Synact Pharma intensifies partnership discussions

Fresh off receiving positive results from a phase IIa study with arthritis candidate AP1189, biotech firm Synact Pharma prepares to look into partnership options.
Photo: Synact Pharma / PR
Photo: Synact Pharma / PR
by christopher due karlsson, translated by daniel pedersen

Synact Pharma is going in with good cards in a hunt for potential partners. Last week, the biotech firm could reveal promising results from a smaller phase IIa study with its drug candidate, AP1189, against arthritis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading